Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)

• Company Description    X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $1.89 Daily Weekly Monthly 20 Day Moving Average: 469,504 shares Shares Outstanding: 5.79 (millions) Market Capitalization: $10.94 (millions) Beta: 0.54 52 Week High: $26.96 52 Week Low: $1.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -48.92% -51.69% 12 Week -70.26% -75.05% Year To Date -91.42% -91.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 61 North Beacon Street 4th Floor - Boston,MA 02134 USA ph: 857-529-8300 fax: - daniel@lifesciadvisors.com http://www.x4pharma.com

• General Corporate Information    Officers Paula Ragan - President and Chief Executive Officer Michael S. Wyzga - Chairman Adam S. Mostafa - Chief Financial Officer and Treasurer William E. Aliski - Director Gary J. Bridger - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98420X202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 5.79 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.54 Market Capitalization: $10.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.62 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-9.54 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.48 Price/Cash Flow: - Price / Sales: 0.35 EPS Growth vs. Year Ago Period: 100.51% vs. Previous Quarter: 100.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 1,908.86% ROE 06/30/25 - - 03/31/25 - -181.56 12/31/24 - -321.45 ROA 06/30/25 - - 03/31/25 - -54.36 12/31/24 - -88.01 Current Ratio 06/30/25 - - 03/31/25 - 3.70 12/31/24 - 3.41 Quick Ratio 06/30/25 - - 03/31/25 - 3.58 12/31/24 - 3.33 Operating Margin 06/30/25 - - 03/31/25 - -288.23 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - 46.54 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - 47.58 12/31/24 - -1,452.48 Book Value 06/30/25 - - 03/31/25 - 3.96 12/31/24 - 3.90 Inventory Turnover 06/30/25 - - 03/31/25 - 2.40 12/31/24 - 0.52 Debt-to-Equity 06/30/25 - - 03/31/25 - 3.30 12/31/24 - 3.41 Debt-to-Capital 06/30/25 - - 03/31/25 - 76.72 12/31/24 - 77.30

Powered by Zacks Investment Research ©